ArticleNanomaterials (Basel, Switzerland)2018
Development of Resveratrol-Loaded Herbal Extract-Based Nanocomposites and Their Application to the Therapy of Ovarian Cancer.
Article in Nanomaterials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Bioinspired and stimuli-responsive nanocomposites for targeted therapy in ovarian and endometrial tumors.International journal of pharmaceutics: X · 2026Review
- Cytotoxic Activity of Curcumin- and Resveratrol-Loaded Core-Shell Systems in Resistant and Sensitive Human Ovarian Cancer Cells.International journal of molecular sciences · 2024Article
- Chemistry, Pharmacology and Therapeutic Potential of Decursin: A Promising Natural Lead for New Drug Discovery and Development.Drug design, development and therapy · 2024Review
- A comprehensive review of the anticancer effects of decursin.Frontiers in pharmacology · 2024Review
- Resveratrol-loaded nanomedicines for cancer applications.Cancer reports (Hoboken, N.J.) · 2021Review
- Improved solubility, dissolution rate, and oral bioavailability of main biflavonoids fromDrug delivery · 2020Article
- Possible contribution of sialic acid to the enhanced tumor targeting efficiency of nanoparticles engineered with doxorubicin.Scientific reports · 2020Article
- RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy.Drug design, development and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resveratrol (RSV) and the ethanol extract of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.